Advertisement

Zeitschrift für Kardiologie

, Volume 94, Issue 8, pp 516–523 | Cite as

Catheter-based septalablation for symptomatic hypertrophic obstructive cardiomyopathy:

Follow-up results of the TASH-registry of the German Cardiac Society
  • L. Faber
  • H. Seggewiss
  • F. H. Gietzen
  • H. Kuhn
  • P. Boekstegers
  • L. Neuhaus†
  • L. Seipel
  • D. Horstkotte
ORIGINAL PAPER

Summary

Introduction

In late 1997, the German Cardiac Society set up a multicenter registry to evaluate the acute and mid-term course of all patients (pts.) treated with septal ablation for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). An analysis of the acute results has already been published. We now report on the mid-term course (3–6 months) of 242 pts. registered through September 1999.

Results

Follow-up was 92% complete (n=222). During follow-up (mean: 4.9±2.3 months), an additional 3 pts. died (in-hospital mortality: 3 pts.). A satisfactory clinical effect was reported by 195 pts. (88%); 27 pts. (12%) remained in NYHA classes III and IV. Overall symptomatic improvement (NYHA class: from 2.8±0.7 to 1.7±0.7) paralleled the outflow gradient (LVOTG) reduction which was further accentuated as compared with the acute result (Doppler measurement at rest: from 57±31 to 25±25 mmHg to 20±21 mmHg; with provocation: from 107±53 to 49±40, to 44±40 mmHg, p<0.001, resp.). Left atrial (LA) diameter (from 46±8 to 44±7 mm) and septal thickness (from 20±5 to 15±5 mm; p<0.001, resp.) were also reduced. Comparing the methods for target vessel selection (i.e., with contrast echo monitoring vs pressurefluoroscopy guidance), at followup clinical improvement and hemodynamic measurements were comparable.

Conclusion

Clinical success can be achieved by septal ablation, both with the echocontrast guided and gradient-fluoroscopy guided method, in 88% of highly symptomatic HOCM pts. At mid-term follow-up, symptoms, left atrial size and septal thickness are reduced, and outflow gradients are further improved as compared to the acute result.

Key words

Hypertrophic obstructive cardiomyopathy percutaneous transluminal septal myocardial ablation transcoronary ablation of septal hypertrophy left ventricular outflow tract gradient DDD-pacemaker total atrioventricular block 

Katheter-basierte Septumablation bei symptomatischer hypertropher obstruktiver Kardiomyopathie: Follow-up—Ergebnisse des TASH-Registers der Deutschen Gesellschaft für Kardiologie

Zusammenfassung

Einleitung

Im Herbst 1997 richtete die Deutsche Gesellschaft für Kardiologie ein bundesweites Register ein, das den Hospital- und mittelfristigen Verlauf bei mittels perkutaner Septumablation behandelten Patienten (Pat.) mit hypertropher obstruktiver Kardiomyopathie (HOCM) erfassen sollte. Die Analyse des Hospitalverlaufs liegt inzwischen vor. Wir berichten jetzt über den mittelfristigen Verlauf (3–6 Monate) der bis September 1999 eingeschlossenen Patienten.

Ergebnisse

Rückmeldungen lagen für 222 von 242 initial erfassten Pat. vor (92%). Im Follow-up-Zeitraum (4,9±2,3 Monate) verstarben 3 weitere Pat. (Hospitalmortalität: 3 Pat. (1,2%)). Über einen zufriedenstellenden Effekt der Intervention berichteten 195 Pat. (88%). Die akut erreichte Senkung des LVOT-Gradienten (LVOTG) von 57±31 auf 25±25 mmHg in Ruhe und von 107±53 auf 49±40 mmHg unter Provokation war nach 3–6 Monaten weiter akzentuiert (auf 20±21 mmHg in Ruhe bzw. 44±40 mmHg unter Provokation, p sämtlich <0,001), was für ein zeitabhängiges lokales Remodeling im Bereich der septalen Zielregion spricht. LA-Diameter (von 46±8 auf 44±7 mm), Septumdicke (von 20±5 auf 15±5 mm) und Dyspnoe, klassifiziert nach NYHA (von 2,8±0,7 auf 1,7±0,7) nahmen ebenfalls ab (p jew. <0,001). Interventionen unter Einschluss der intra-prozeduralen Echokardiographie sowie solche mit angiographisch/ durch Druckmessung erfolgender Steuerung waren hinsichtlich der klinischen Besserung und der invasiven Resultate vergleichbar.

Schlussfolgerung

Im mittelfristigen Verlauf nach Kathetertherapie, sowohl kontrastechokardiographisch wie auch per Druckmessung/fluoroskopisch gesteuert, bestätigen sich die positiven Akutergebnisse mit einem weiteren Absinken des LVOTG. LA-Last und Septumdicke nehmen ab, die körperliche Belastbarkeit nimmt weiter zu.

Schlüsselwörter

Hypertrophe obstruktive Kardiomyopathie transkoronare Ablation der Septumhypertrophie perkutane transluminale septale Myokardablation Obstruktion des linksventrikulären Ausflusstrakts totaler AV-Block DDD-Schrittmacher 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. Eur Heart J 24:1965–1991Google Scholar
  2. 2.
    Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G (2001) Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:846–853CrossRefPubMedGoogle Scholar
  3. 3.
    Braunwald E (1997) Induced septal infarction: A new strategy for hypertrophic obstructive cardiomyopathy. Circulation 95:1981PubMedGoogle Scholar
  4. 4.
    Chang SM, Lakkis NM, Franklin J, Spencer WHIII, Nagueh SF (2004) Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 109:824–827CrossRefPubMedGoogle Scholar
  5. 5.
    Cheitlin, MD, Armstrong, WF, Aurigemma GP et al (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 108:1146CrossRefPubMedGoogle Scholar
  6. 6.
    Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intra-procedural myocardial contrast echocardiography. Circulation 98:2415–2421PubMedGoogle Scholar
  7. 7.
    Faber L, Seggewiss H, Fassbender D, Bogunovic N, Strick S, Schmidt HK, Gleichmann U (1998) Perkutane transluminale septale Myokardablation bei HOCM: Akutergebnisse bei 66 Patienten unter Berücksichtigung der Myokard-Kontrastechokardiographie. Z Kardiol 87:191–201CrossRefGoogle Scholar
  8. 8.
    Faber L, Meissner A, Ziemssen P, Seggewiss H (2000) Percutaneous transluminal septal myocardial ablation for HOCM: Long-term follow-up in the first series of 25 patients. Heart 83:326–331CrossRefPubMedGoogle Scholar
  9. 9.
    Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, Gleichmann U, Horstkotte D (2003) Vorhersage des Risikos permanenter atrioventrikulärer Überleitungsstörungen nach perkutaner Septumablation bei Patienten mit hypertropher obstruktiver Kardiomyopathie. Z Kardiol 92:39–45CrossRefPubMedGoogle Scholar
  10. 10.
    Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH 3rd, Nagueh SF (2001) Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 37:208–214CrossRefPubMedGoogle Scholar
  11. 11.
    Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H (2002) Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation 106:454–459CrossRefPubMedGoogle Scholar
  12. 12.
    Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn H (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J 20:1342–1354CrossRefPubMedGoogle Scholar
  13. 13.
    Heric B, Lytle BW, Miller OP (1995) Surgical management of hypertrophic obstructive cardiomyopathy. J Thor Cardiovasc Surg 110:195–208Google Scholar
  14. 14.
    Kimmelstiel CD, Maron BJ (2004) Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 109:452–456CrossRefPubMedGoogle Scholar
  15. 15.
    Knight CJ, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U (1997) Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 95:2075–2081PubMedGoogle Scholar
  16. 16.
    Kuhn H, Gietzen F, Leuner C, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846–851PubMedGoogle Scholar
  17. 17.
    Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L (2004) Catheter-based therapy for hypertrophic obstructive cardiomyopathy: First in-hospital outcome analysis of the German TASH Registry Z Kardiol 93:23–31CrossRefPubMedGoogle Scholar
  18. 18.
    Kuhn H, Gietzen FH, Leuner C, Schaefers M, Schober O, Strunk-Mueller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(Suppl 4):IV41–54CrossRefPubMedGoogle Scholar
  19. 19.
    Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED et al (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687–1713CrossRefPubMedGoogle Scholar
  20. 20.
    Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik JA, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:1707–1710CrossRefPubMedGoogle Scholar
  21. 21.
    Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD (2001) Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 38:1994–2000CrossRefPubMedGoogle Scholar
  22. 22.
    Robbins RC, Stinson EB, Daily PO (1996) Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111:586–594PubMedGoogle Scholar
  23. 23.
    Sahn DJ, De Maria AN, Kisslo J, Weyman A (1978) The committee on m-mode standardization of the American Society of Echocardiography. Circulation 58:1072–1078PubMedGoogle Scholar
  24. 24.
    Schulte HD, Gramsch-Zabel H, Schwartzkopff B (1995) Hypertrophische obstruktive Kardiomyopathie: Chirurgische Behandlung. Schweiz Med Wochenschr 125:1940–1949PubMedGoogle Scholar
  25. 25.
    Schulte HD, Bircks W, Lösse B (1987) Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM), Z Kardiol 76(supp 3):145–151PubMedGoogle Scholar
  26. 26.
    Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-months follow-up in 25 patients. J Am Coll Cardiol 31:252–258CrossRefPubMedGoogle Scholar
  27. 27.
    Seggewiss H (2001) Current status of alcohol septal ablation for patients with hypertrophic obstructive cardiomyopathy. Curr Cardiol Rep 3:160–166PubMedGoogle Scholar
  28. 28.
    Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214CrossRefPubMedGoogle Scholar
  29. 29.
    Spencer WH 3rd, Roberts R (2000) Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: the need for a registry. Circulation 102:600–601PubMedGoogle Scholar
  30. 30.
    Spirito P, Seidman CE, Mc Kenna WJ, Maron BJ (1997) The managemant of hypertrophic cardiomyopathy. New Engl J Med 336:775–785CrossRefPubMedGoogle Scholar
  31. 31.
    Wigle DE, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 92:1680–1692PubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2005

Authors and Affiliations

  • L. Faber
    • 1
  • H. Seggewiss
    • 2
  • F. H. Gietzen
    • 3
  • H. Kuhn
    • 4
  • P. Boekstegers
    • 5
  • L. Neuhaus†
    • 6
  • L. Seipel
    • 7
  • D. Horstkotte
    • 1
  1. 1.Kardiologische Klinik Herz- und Diabeteszentrum NRWUniversitätsklinik der Ruhr-Universität BochumBad OeynhausenGermany
  2. 2.Leopoldina-KrankenhausSchweinfurtGermany
  3. 3.Klinik für KardiologieHerz- und Gefäß-Klinik Bad Neustadt/SaaleBad Neustadt/SaaleGermany
  4. 4.Klinikum Bielefeld-MitteBielefeldGermany
  5. 5.Klinikum der UniversitätMünchen-GroßhadernGermany
  6. 6.Klinikum KasselKasselGermany
  7. 7.Medizinische Klinik/Kardiologie der UniversitätTübingenGermany

Personalised recommendations